Reduction in breathlessness
SPIOLTO® RESPIMAT® provided a 52% improvement in breathlessness vs SPIRIVA® in GOLD 2-3 patients.1
Change in breathlessness after 12 weeks, measured by Mahler TDI focal score in patients at GOLD 2-31*†
Adapted from reference 1
Significant improvements in breathlessness with SPIOLTO® RESPIMAT® were most apparent in the GOLD 2 patient population, demonstrating the benefits for patients with moderate disease.3
Reduced need for rescue medication
Once-daily SPIOLTO® RESPIMAT® consistently reduced patients’ need for rescue medication compared to SPIRIVA®. Patients treated with SPIOLTO® RESPIMAT® used 22% less daytime and 26% less night-time rescue salbutamol vs patients treated with SPIRIVA®.4
- Singh D, et al. Respir Med 2015;109:1312-1319 and supplementary information.
- Witek TJ, Mahler DA. Eur Respir J. 2003; 21: 267-272.
- Singh D et al. Resp Res 2016;17(73):1-13 and supplementary information.
- SPIOLTO® RESPIMAT® Summary of Product Characteristics February 2017.